Treatment of post‐treatment Lyme disease symptoms—a systematic review
European Journal of Neurology · 2024-07 · 31 (7)
DOI: 10.1111/ene.16293 ↗At a glance
Systematische Übersicht in European Journal of Neurology, published online on 2024-04-12. Written by Rick Dersch and 2 co-authors. Institution: Clinic of Neurology and Neurophysiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Major MEDLINE topics: Lyme Disease. Cited 17 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: German Neurological Society.
Abstract (original language)
Background and purpose Residual symptoms after treatment of Lyme disease, sometimes called post‐treatment Lyme disease symptoms (PTLDs), are a matter of ongoing controversy. To guide treatment recommendations, a systematic review was performed of the available literature on specific treatment for PTLDs.
Methods
A systematic literature search of MEDLINE and CENTRAL was performed. No restrictions on case definitions, study types or specific interventions were applied to enable a comprehensive overview of the available literature. Risk of bias was assessed using the Cochrane risk of bias tools for randomized controlled trials. Certainty of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. Outcomes of interest were quality of life, fatigue, depression and cognition as well as adverse events.
Results
After screening 1274 records, eight eligible randomized controlled trials were included. Heterogeneity was observed regarding inclusion criteria, intervention, length of treatment and outcome measures. For efficacy outcomes, results are presented narratively due to heterogeneity. Eligible studies show no statistically significant difference between antibiotics and placebo regarding quality of life, cognition and depression. Results for fatigue were inconsistent whilst studies with low risk of bias showed no statistically significant difference between antibiotics and placebo. Meta‐analysis of safety outcomes showed statistically significantly more adverse events for antibiotics compared to placebo.
Conclusions
Available literature on treatment of PTLDs is heterogeneous, but overall shows evidence of no effect of antibiotics regarding quality of life, depression, cognition and fatigue whilst showing more adverse events. Patients with suspected PTLDs should not be treated with antibiotics.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Clinic of Neurology and Neurophysiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Department of Pediatrics, Paracelsus Medical University, Klinikum Nürnberg, Universitätsklinik der Paracelsus Medizinischen Privatuniversität Nürnberg, Nuremberg, Germany.
ORCID profiles: Rick Dersch, Gabriel Torbahn
Funding
- German Neurological Society
Cite
APA
Dersch, R., Torbahn, G., & Rauer, S. (2024). Treatment of post‐treatment Lyme disease symptoms—a systematic review. European Journal of Neurology, 31(7). https://doi.org/10.1111/ene.16293
Vancouver
Dersch R, Torbahn G, Rauer S. Treatment of post‐treatment Lyme disease symptoms—a systematic review. European Journal of Neurology. 2024;31(7). doi:10.1111/ene.16293
BibTeX
@article{Dersch2024,
author = {Dersch, Rick and Torbahn, Gabriel and Rauer, Sebastian},
title = {Treatment of post‐treatment Lyme disease symptoms—a systematic review},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {7},
doi = {10.1111/ene.16293}
}
EUVIMED